The invention provides methods of treating a bacterial infection in a mammal comprising administering to the mammal a substituted bicyclic heteroaromatic ring compound of formula I: wherein two of X1 to X8 are N and the remaining of X1 to X8 are CH; or a pharmaceutically acceptable salt thereof, as well as novel compounds of formula I and salts thereof and pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof.
The invention provides methods of treating a bacterial infection in a mammal comprising administering to the mammal a substituted bicyclic heteroaromatic ring compound of formula I: wherein two of X
1
to X
8
are N and the remaining of X
1
to X
8
are CH; or a pharmaceutically acceptable salt thereof, as well as novel compounds of formula I and salts thereof and pharmaceutical compositions comprising a compound of formula I or a pharmaceutically acceptable salt thereof.
US9822108B2
申请人:——
公开号:US9822108B2
公开(公告)日:2017-11-21
Antibacterial activity of quinoxalines, quinazolines, and 1,5-naphthyridines
作者:Ajit K. Parhi、Yongzheng Zhang、Kurt W. Saionz、Padmanava Pradhan、Malvika Kaul、Kalkal Trivedi、Daniel S. Pilch、Edmond J. LaVoie
DOI:10.1016/j.bmcl.2013.06.048
日期:2013.9
Several phenylsubstituted naphthalenes and isoquinolines have been identified as antibacterial agents that inhibit FtsZ-Zing formation. In the present study we evaluated the antibacterial of several phenylsubstituted quinoxalines, quinazolines and 1,5-naphthyridines against methicillin-sensitive and methicillin-resistant Staphylococcus aureus and vancomycin-sensitive and vancomycin-resistant Enterococcus